Clinical Trials Logo

Obesity clinical trials

View clinical trials related to Obesity.

Filter by:
  • Withdrawn  
  • Page 1 ·  Next »

NCT ID: NCT05834062 Withdrawn - Obesity, Adolescent Clinical Trials

Phentermine/Topiramate as Preventive Pharmacotherapy for Obesity

Start date: October 17, 2023
Phase: Phase 2
Study type: Interventional

This study will test the use of phentermine and topiramate compared with placebo in helping adolescents who are at high risk for developing obesity to lose weight

NCT ID: NCT05833464 Withdrawn - Obesity Clinical Trials

Cost-effectiveness Study of a Multidisciplinary Weight Loss Method to Improve the Health Condition of Obese Patients

PRONOCOST
Start date: May 2018
Phase:
Study type: Observational [Patient Registry]

Prospective, observational, multicenter study based on a registry of patients with obesity and associated comorbidities undergoing a standardized multidisciplinary weight loss method with a 2-year follow-up.

NCT ID: NCT05747105 Withdrawn - Obesity Clinical Trials

A Sleep Extension Pilot Study in Adults With Obesity

Start date: February 7, 2023
Phase: N/A
Study type: Interventional

The pilot study will test the feasibility of a 16-week sleep extension intervention, in adults with obesity, to increase nighttime sleep duration, as well as reduce daytime sleepiness and sleep-related disturbance. The study will also examine changes in weight, eating behaviors, wellbeing, and blood pressure across the 16-week intervention .

NCT ID: NCT05720377 Withdrawn - Obesity Clinical Trials

Evaluation of Exercise Application Technology in Adolescents

Start date: February 1, 2024
Phase: N/A
Study type: Interventional

The purpose of the study is to evaluate the use of an exercise phone application and a continuous glucose monitor and their impact on metabolic disease in adolescents with obesity, prediabetes and Type 2 diabetes. Participants will be asked to wear a continuous glucose monitor (Freestyle Libre) and if they are in the intervention group also participate in using an exercise phone application as well as have scheduled interval contact with a health professional in between scheduled clinic visits to assess how they are reaching their goals.

NCT ID: NCT05663554 Withdrawn - Obesity Clinical Trials

Improving Glycemic Control Using a Virtual Weight Control Program Among Adults With Type 2 Diabetes

VITAL-2
Start date: January 15, 2023
Phase: N/A
Study type: Interventional

The study is a randomized clinical trial with the primary aim of determining the effectiveness of the WW intervention at reducing HbA1c in patients with type 2 diabetes.

NCT ID: NCT05553405 Withdrawn - Obesity Clinical Trials

Neuroimmune Mechanisms in Obesity

Start date: January 1, 2024
Phase: Phase 1
Study type: Interventional

Aim 1: To measure levels of microglia using the radiotracer [11C]PBR28 and PET brain imaging in obese (n=50) vs. lean individuals (n=50). The investigators will recruit 100 subjects who will participate in a single [11C]PBR28 scan to measure levels of TSPO, a marker of microglia. Aim 2: To determine differences in brain functional connectivity at rest and in response to a decision- making task in obese (n=50) vs. lean individuals (n=50) using fMRI imaging. The same subjects from Aim 1 will participate in a resting state functional magnetic resonance imaging (fMRI) followed by a decision making task during fMRI acquisition. Aim 3: To assess whether acute elevation of lipid levels through intralipid infusion in lean, healthy individuals (n=20) will induce microglial activation. 20 lean individuals will be recruited to participate in a paradigm that includes a baseline [11C]PBR28 scan, an infusion of intralipid, and a second [11C]PBR28 scan approximately 4 hours post intralipid infusion. The investigators will attempt to utilize subjects from aim 1 in order to use their baseline scans for this paradigm. Aim 4: To determine whether there are differences in levels of microglia between individuals with and without type 1 diabetes (n=20). 20 patients with diabetes (type 1 diabetes or type 2 diabetes)will be recruited to participate in a single [11C]PBR28 scan to compare to Aim 1 participants.

NCT ID: NCT05457530 Withdrawn - Obesity Clinical Trials

Doravirine and Weight Gain in Antiretroviral Naive

DAWN
Start date: August 1, 2022
Phase: Phase 3
Study type: Interventional

The purpose of this study is determine whether different antiretroviral therapy (ART) changes the effects on body fat and predict the weight change in Black and Hispanic females.

NCT ID: NCT05438186 Withdrawn - Obesity Clinical Trials

INSPIRE Turkey :A Research Study Looking at the Clinical Parameters Associated With Use and Discontinuation of Saxenda® in Local Clinical Practice in Turkey by Analysing Past Patient Medical Records

INSPIRE Turkey
Start date: September 1, 2022
Phase:
Study type: Observational

The study is investigating the use of Saxenda (liragltuide 3.0 milligrams (mg) once daily) for weight management. The primary objective is to investigate the change in body weight after initiation and use of Saxenda ® according to local clinical practice for weight management, on adult participant's in a real world setting in Turkey. The study will last for about 5 months.

NCT ID: NCT05219890 Withdrawn - Obesity Clinical Trials

Transcriptomics of Mononuclear Cells and Inflammatory Status of Obese Patients Treated With Omega-3 Fatty Acids

Start date: January 16, 2017
Phase: N/A
Study type: Interventional

The main objective is to determine the effect that supplementation with 4.8 g/day of w-3 FA [3.2g eicosapentaenoic acid (EPA) and 1.6 g docosahexaenoic acid (DHA)] have on the inflammatory state of obese patients (BMI ≥ 35.0 kg/m2), at the metabolic, cellular and molecular levels.

NCT ID: NCT05147415 Withdrawn - Clinical trials for Hypothalamic Obesity

Study of Tesomet With Open-label Extension in Subjects With Hypothalamic Obesity (HO)

Start date: November 11, 2021
Phase: Phase 2
Study type: Interventional

This study will evaluate the safety and efficacy of Tesomet (tesofensine + metoprolol) in subjects 18 years of age or older, with HO